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For many years toxemia has served 
as a wastebasket for a variety of dis-
ease states characterized by an ele-
vated arterial pressure, edema, and 
albuminuria. Whereas this triad is con-
sistent with the diagnosis of toxemia, 
it is not diagnostic. Besides toxemia, 
these abnormalities may be found in 
pregnant patients with hypertensive 
vascular disease, pyelonephritis, glo-
merulonephritis, or any combination 
of these (fig. 1). Data derived from 
studies performed on patients with 
such a variety of disease entities have 
obviously been confusing. It makes a 
lot of difference, for example, whether 
the subjects studied had chronic pyelo-
nephritis or acute vasospastic toxemia. 
During the past 13 years, our group 
has attempted to cut the pie of ele-
vated arterial pressure, albuminuria, 
and edema into separate and distinct 
diagnostic pieces. Ophthalmoscopic 
examination and urinalysis have been 
of great help in this regard (Finnerty, 
1954, 1956 and 1965; Finnerty et al. , 
1960). 
Diagnosis 
Toxemia was diagnosed when the 
ophthalmoscopic examination revealed 
spasm of the retinal arteries with no 
retinopathy, and urinalysis revealed 
only albuminuria (fig. 2). Hypertensive 
vascular disease existed when the reti-
nal arteries were either normal or 
thickened and tortuous with AV nick-
ing. When both signs of chronic vas-
cular disease and acute vasospasm 
were observed with or without albu-
minuria, toxemia was then superim-
posed on hypertensive vascular disease. 
* Presented at the Thirty-sixth Annual 
McGuire Lecture Series at the Medical 
College of Virginia, October 8, 1964. 
32 
The finding of normal fundi and al-
buminuria suggested pyelonephritis. 
Clumps of cells in the urine and a posi-
tive colony count documented the diag-
nosis. 
Figure 3 gives the diagnostic break-
down in 4,273 patients followed in our 
toxemia clinic during the past 3 years. 
It is interesting to note the frequency 
of pyelonephritis and hypertensive vas-
cular disease, and the relative rarity 
of true toxemia. The recent biopsy 
studies of Altchek (1961) would seem 
to substantiate the finding that most 
patients originally thought to have tox-
emia actually have some other disease. 
The specific biopsy picture for toxemia 
has for the first time significantly clar-
ified this wastebasket of syndromes. It 
would seem that toxemia is another 
type of glomerulonephritis. Figure 4 
shows the similarity between toxemia 
and glomerulonephritis. Both diseases 
are characterized by a greater rise in 
the diastolic than the systolic pressure, 
which causes a narrow pulse pressure. 
The edema is particularly in the peri-
orbital areas, hands and feet. Ophthal-
moscopic examination reveals thread-
Fig.1.-Elevated blood pressure, al-
buminuria and edema are seen in toxemia 
but also in several other conditions. 
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Fig. 2-0phthalmoscopic examination and urinalysis in the differential diagnosis of 
toxemia. 
THE DIAGNOSIS IN 4 273 PATIENTS 
1961 - 1963 
PURE TOXEMIA ••••••••••••••••••••.••...••.•.•.•..• 167 
TOXEMIA+ HYPERTENSIVE VASCULAR DISEASE ....... 42 6% 
TOXEMIA+ PYELONEPHRITIS ...................... . . 67 
PYELONEPHRITIS •••••••.•.•....•...•......••....... 704 25% 
PYELONEPHRITIS +HYPERTENSIVE VASC . DISEASE ... 287 
HYPERTENSIVE VASCULAR DISEASE .. . ... . ........... 804 
GLOMERULONEPHR ITI S •••••.•.•.•..••.•.•. • .......•. 84 
NON-RELATED MEDICAL DISEASE ..................... 214 
(ANEMIA, HEART DISEASE, ETC.) 
EDEMA WITHOUT DISEASE. ....... . ....... . .......... 387 
ASYMPTOMATIC BACTERURIA ••...••.• • •.•. • . • .•.••.. 469 
NO DISEASE •••.••••••..••••...... • .....••......•... 944 
QUESTIONABLE DIAGNOSIS ••••.••.•••. • ...•••....... 104 
TOT AL T,273 
Fig. 3-Diagnostic features in patients attending the toxemia clinic 
like arteries and generalized wetness of 
the retina. Both diseases are character-
ized by albuminuria. 
Pathologic Physiology 
All the signs and symptoms of tox-
emia may be adequately explained by 
abnormal sodium retention and gen-
eralized vasoconstriction (fig. 5). The 
relationship between the two is un-
known, but clinical observation attests 
that sodium retention usually precedes 
generalized vasoconstriction, and that 
prompt therapy of sodium retention 
usually prevents generalized vasocon-
striction. The studies of Eisenberg 
(1959) in patients with acute nephritis, 
and Finnerty (1962) in patients with 
toxemia, show that there is an increase 
in plasma volume without an increase 
in circulating red cell mass. Following 
diuretic therapy the plasma volume re-
turns to normal. This pattern of blood 
volume expansion, therefore, contrasts 
sharply with that in patients with con-
gestive heart failure in whom there is 
a commensurate increase in red cell 
mass and plasma volume. These data 
suggest that an abnormality of salt and 
water metabolism is solely responsible 
for the hypervolemia of acute nephri-
tis and toxemia. 
A decrease in the amount of blood 
to a particular area due to increased 
vasoconstriction explains the remain-
der of the abnormality. An increase in 
cerebral vasoconstriction causes cere-
bral ischemia, leading to coma and 
convulsions. It is interesting in this re-
gard to emphasize that it is cerebral 
ischemia, and not a rise in arterial 
pressure, that is the important abnor-
mality in inducing coma and convul-
sions. The exact same symptoms may 
be caused by postural hypotension or 
an attack of Stokes-Adams syncope. 
Evidence of both sodium retention 
and vasoconstriction, the two patho-
physiologic abnormalities, can be vis-
ualized ophthalmoscopically. A wet, 
glistening appearance of the entire 
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retina (retinal sheen) and a decrease in 
the caliber of the retinal arteries char-
acterize toxemia. The observation that 
the generalized sheen of toxemia is 
promptly decreased following diuretic 
therapy strongly suggests that it repre-
sents retinal edema. 
Increased constriction of the pe-
ripheral vessels seems to account for 
the elevated arterial pressure. The in-
crease in arterial pressure in toxemia 
is not associated in a change in the 
cardiac output. Finally, the increased 
vasoconstriction in the renal circula-
tion, particularly in the afferent vessels 
as noted by Assali et al. (1953) ac-
counts, in part at least, for the de-
crease in urinary output. The decrease 
in urinary output is part of the toxemic 
process and not necessarily a compli-
cation. 
In summary, then, the toxemic proc-
ess can be divided into two phases: 
the sodium retention phase, and the 
phase of sodium retention plus gen-
eralized vasoconstriction (fig. 6). The 
sodium retention phase is character-
ized by an increase in plasma volume 
which returns to normal following 
therapy. Prompt therapy will fre-
quently prevent the development of the 
second phase. 
Therapy 
The availability of the thiazides has 
completely changed the concept of the 
treatment of toxemia. Prior to their 
development, the primary aim of ther-
apy of toxemia was directed toward 
the control of arterial pressure and 
albuminuria (manisfestations of gen-
eralized vasoconstriction). Reserpine, 
hydralazine, and veratrum, therefore, 
were used extensively in our clinic, as 
well as in others. If the arterial pres-
sure could not be lowered sufficiently, 
additional antihypertensive agents were 
added. 
The primary aim of therapy of tox-
emia, at present, is prompt control of 
sodium retention. The effectiveness of 
the thiazides in immediately control-
ling abnormal sodium retention, and in 
returning the plasma volume to nor-
mal, has frequently prevented the de-
velopment of generalized vasoconstric-
tion and thereby practically eliminated 
the need of antihypertensive therapy 
in these patients. When used alone at 
the first sign of excessive weight gain, 
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Fig. 5-Pathogenesis of toxemia 
the thiazides frequently reverse the 
toxemic process. Even more important 
is the observation that they can be ad-
ministered continuously without the 
development of drug resistance, thus 
preventing the development of vaso-
constriction. For practical purposes, 
the prevention of vasoconstriction is 
equivalent to the preventing of toxe-
mia. In our experience, these diuretic 
agents have resulted in more than a 
70% reduction in the number of pa-
tients with toxemia during the past 
two years. 
If signs of vasoconstriction (retinal 
arterial spasm and albuminuria or 
either of them alone) are already pres-
ent when the patient first presents her-
self, she probably should be hospital-
ized. It should be stressed that the 
primary aim of therapy in the hos-
pitalized patient is preparation of the 
patient for delivery or Cesarean sec-
tion. Whereas for the out-patient, so-
dium diuretics are the only agents 
needed, in the hospitalized patient 
these drugs serve only as background 
agents. Vasodilating agents must now 
also be administered. 
We have recently had experience 
with a nondiuretic benzothiadiazine 
analogue whose structural formula is 
very similar to chlorothiazide (fig. 7). 
When administered by mouth it causes 
only a small reduction in arterial pres-
sure, and also causes sodium retention 
and hyperglycemia. When adminis-
tered by vein, however, it is a potent 
vasodilating agent. The average effec-
tive dosage is 300 mg (1 ampule) given 
rapidly, undiluted. To date, 69 patients 
with severe pre-eclampsia and 2 with 
eclampsia have received diazoxide 
with excellent results. The typical ef-
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Fig. 6-Two Main phases of toxemia 
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feet of 300 mg of diazoxide can be 
seen in figure 8. A 35% average reduc-
tion in mean arterial pressure occurred 
during the first 2 minutes. During the 
next 3 to 5 minutes, the arterial pres-
sure increased gradually, leveling off 
at 19% average reduction as com-
pared with the control. No signs of 
postural hypotension, cerebral ische-
mia, or collapse were noted. 
The fall in arterial pressure with 
diazoxide is consistently associated 
with an increase in cardiac output, and 
a decrease in total peripheral resist-
ance. From the cardiac and cerebral 
hemodynamic standpoint, diazoxide 
resembles hydralazine since both 
agents cause an increase in cardiac 
output, heart rate, and cerebral blood 
flow. Actual cerebral blood flow de-
terminations have not been performed 
in this laboratory, but the lack of 
signs of cerebral ischemia accompany-
ing the reduction in arterial pressure, 
and the increase in cardiac output, 
strongly indicate that there is at least 
maintenance of the cerebral blood 
flow, even at the point of the greatest 
magnitude of hypotensive action. 
Our experience thus far would indi-
cate that diazoxide represented a real 
advance in the therapy of acute vaso-
spastic hypertension. 
Prevention 
Experience has shown that it is 
easier to prevent toxemia than to treat 
it. Although the thiazide diuretics seem 
to be the ideal agents for the treatment 
of the sodium retention phase of tox-
emia, their greatest asset is that they 
can be given continuously without the 
problem of drug resistance. I feel, 
therefore, that the thiazides should 
not only be given at the first sign of 
sodium retention, but should be insti-
tuted from the tenth week of preg-
nacy in patients who are candidates for 
toxemia, e.g., patients with chronic hy-
pertensive vascular disease, patients 
with chronic renal disease, and proba-
bly all primagravida patients. The data 
on more than 6,000 patients treated 
with thiazides has shown that the con-
tinued use of these drugs following 
the tenth week of pregnancy appar-
ently is not harmful to the fetus. 
FRANK A. FINNERTY, JR. 
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